ByTrending Posts
Can GSK’s 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — GlaxoSmithKline PLC (GSK) achieved key milestones in 2025, with multiple regulatory approvals, product…
Can AstraZeneca’s 2025 Launches and Approvals Strengthen Its…
Global | January 2026 — AstraZeneca PLC achieved significant milestones in 2025, marked by multiple regulatory approvals, label…
Can Novo Nordisk’s 2025 Diabetes, Obesity, and Rare…
Global | January 2026 — Novo Nordisk A/S continued to reinforce its leadership in diabetes, obesity, and rare…
Can Roche’s 2025 Launches and Approvals Reinforce Its…
Global | January 2026 — Roche Holding AG achieved a strong year in 2025, marked by multiple regulatory…
Can Novartis’ 2025 Approvals and Launches Strengthen Its…
Global | January 2026 — Novartis AG advanced its strategic portfolio in 2025 with multiple product approvals and…
Can Johnson & Johnson’s 2025 Product Momentum and…
Global | January 2026 — Johnson & Johnson continued to reinforce its position as one of the world’s…
Can Gilead’s 2025 Approvals and Targeted Launches Reinforce…
Global | January 2026 — Gilead Sciences, Inc. strengthened its innovation-led growth profile in 2025 through a focused…
Can AbbVie’s 2025 Launches and Portfolio Expansion Offset…
Global | January 2026 — AbbVie Inc. accelerated its post-Humira transformation in 2025, advancing a diversified portfolio across…
Can Merck’s 2025 Launches, Label Expansions, and Oncology…
Global | January 2026 — Merck & Co., Inc. (MSD outside the U.S. and Canada) reinforced its position…
Trending Posts
Latest Stories
Can Johnson & Johnson’s $550 Million Vision Care Expansion Drive Local Growth and Innovation?
23 January 2026 Executive Summary Johnson & Johnson’s Vision Care division is advancing a major…
Can Johnson & Johnson Hit $100 Billion in Revenue Despite U.S. Pricing Pressures?
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug Discovery?
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex,…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate Receptor-Targeted Ovarian Cancer Candidate
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration…
Gallery
